The cost-effectiveness of real-time continuous glucose monitoring versus intermittently scanned continuous glucose monitoring in individuals with insulin-treated Type 2 diabetes mellitus in Canada
Journal of Comparative Effectiveness Research · 2025
DOI: 10.57264/cer-2025-0125 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Comparative Effectiveness Research, 2025. Verfasst von Michael Willis und 4 weiteren Autor:innen. Beteiligte Einrichtung: The Swedish Institute for Health Economics, Lund, Sweden. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Blood Glucose Self-Monitoring, Insulin, Hypoglycemic Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aim
Continuous glucose monitoring (CGM) supports glycemic control and reduces diabetes complications. CGM systems include intermittently scanned CGM (is-CGM) and real-time CGM (rt-CGM). While rt-CGM may provide better outcomes than is-CGM, it costs more upfront and its cost-effectiveness in Canada has not been established. We assessed the cost-effectiveness of rt-CGM versus is-CGM in people with insulin-treated Type 2 diabetes mellitus (T2DM) from a Canadian healthcare payer perspective. Materials & methods: We used the ECHO-T2DM microsimulation model to estimate incremental lifetime health outcomes and costs of rt-CGM versus is-CGM. Clinical inputs came from an indirect treatment comparison; cost and utility data were drawn from published sources. Sensitivity analyses tested robustness.
Results
Rt-CGM was more effective and less costly than is-CGM, yielding 0.346 additional quality-adjusted life-years and CAD 2237 in savings over 30 years. Benefits stemmed primarily from better glycemic control and fewer complications, reductions in glycemic events, and reduced fear of hypoglycemia. Although rt-CGM incurred CAD 3867 higher acquisition costs, these were more than offset by avoided complications. Deterministic analysis showed dominance in 14 of 18 scenarios, and cost-effectiveness in the remaining four. Uncertainty analysis showed rt-CGM had an ICER below CAD 50,000 in 98% of simulations.
Discussion
Rt-CGM is potentially a cost-saving alternative to is-CGM among people with insulin-treated T2DM in Canada. This finding was strengthened by rigorous sensitivity analysis. Study strengths include use of a validated microsimulation model and adoption of conservative assumptions. Limitations include absence of head-to-head trial evidence and indirect use of time in and out of range.
Conclusion
Rt-CGM is a potentially cost-saving option for managing insulin-treated T2DM in Canada, with implications for clinical practice and reimbursement policy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Swedish Institute for Health Economics, Lund, Sweden.
- Dexcom Inc, San Diego, CA 92121, USA.
ORCID-Profile: Michael Willis, Andreas Nilsson, Hamza Alshannaq, Jessica Matuoka, Gregory Norman
Zitieren
APA
Willis, M., Nilsson, A., Alshannaq, H., Matuoka, J., & Norman, G. (2025). The cost-effectiveness of real-time continuous glucose monitoring versus intermittently scanned continuous glucose monitoring in individuals with insulin-treated Type 2 diabetes mellitus in Canada. Journal of Comparative Effectiveness Research. https://doi.org/10.57264/cer-2025-0125
Vancouver
Willis M, Nilsson A, Alshannaq H, Matuoka J, Norman G. The cost-effectiveness of real-time continuous glucose monitoring versus intermittently scanned continuous glucose monitoring in individuals with insulin-treated Type 2 diabetes mellitus in Canada. Journal of Comparative Effectiveness Research. 2025. doi:10.57264/cer-2025-0125
BibTeX
@article{Willis2025,
author = {Willis, Michael and Nilsson, Andreas and Alshannaq, Hamza and Matuoka, Jessica and Norman, Gregory},
title = {The cost-effectiveness of real-time continuous glucose monitoring versus intermittently scanned continuous glucose monitoring in individuals with insulin-treated Type 2 diabetes mellitus in Canada},
journal = {Journal of Comparative Effectiveness Research},
year = {2025},
doi = {10.57264/cer-2025-0125}
}
EUVIMED